Literature DB >> 6155687

Natural killer cell response to lymphocytic choriomeningitis virus in beige mice.

R M Welsh, R W Kiessling.   

Abstract

Lymphocytic choriomeningitis virus (LCMV) induced low levels of natural killer (NK) cell acitivity in C57BL6 mutant beige (bg/bg) mice, which had previously been reported to have no cytotoxic NK cells. NK cell-mediated lysis by bg/bg splenocytes was observed against a cell line (YAC-1) very sensitive to NK cell cytotoxicity, but not appreciably against a less sensitive cell line (L-929). The bg/bg mutant mice with this very low NK cell activity and control strains of mice (by/+, C57BL6) with high NK cell activity synthesized comparable amounts of virus and interferon in the spleen, suggesting that NK cells may not play a significant role, but not appreciably against a less sensitive cell line (L-929). The bg/bg mutant mice with this very low NK cell activity and control strains of mice (by/+, C57BL6) with high NK cell activity synthesized comparable amounts of virus and interferon in the spleen, suggesting that NK cells may not play a significant role, but not appreciably against a less sensitive cell line (L-929). The bg/bg mutant mice with this very low NK cell activity and control strains of mice (by/+, C57BL6) with high NK cell activity synthesized comparable amounts of virus and interferon in the spleen, suggesting that NK cells may not play a significant role in curtailing viral synthesis before the advent of the specific immune response mechanisms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155687     DOI: 10.1111/j.1365-3083.1980.tb00001.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  18 in total

1.  SST-2 tumor inoculation is a useful model for studying the anti-tumor immune response in SHR rats.

Authors:  Naomi Nishio; Katsutaka Oishi; Kazuhiko Machida
Journal:  Environ Health Prev Med       Date:  2003-03       Impact factor: 3.674

2.  Natural killer activity in patients with acute viral hepatitis.

Authors:  L Chemello; M Mondelli; F Bortolotti; E Schiavon; P Pontisso; A Alberti; E G Rondanelli; G Realdi
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

3.  Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus.

Authors:  R O Jacoby; P N Bhatt; D G Brownstein
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

4.  Chronic Lymphocytic Choriomeningitis Infection Causes Susceptibility to Mousepox and Impairs Natural Killer Cell Maturation and Function.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Colby Stotesbury; Carolina R Melo-Silva; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

5.  Activation of natural killer cells and induction of interferon after injection of mouse hepatitis virus type 3 in mice.

Authors:  L Schindler; H Engler; H Kirchner
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

Review 6.  Natural killer cells: artifact to reality: an odyssey in biology.

Authors:  R K Oldham
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  Natural killer cells appear to play no role in the recovery of mice from Sindbis virus infection.

Authors:  R L Hirsch
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

8.  Listeriosis in beige mice and their heterozygous littermates.

Authors:  C Cheers; P Wood
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

9.  Mouse adenovirus type 1 infection of natural killer cell-deficient mice.

Authors:  Amanda R Welton; Lisa E Gralinski; Katherine R Spindler
Journal:  Virology       Date:  2007-12-21       Impact factor: 3.616

10.  Toxoplasma-induced activities of peritoneal and spleen natural killer cells from beige mice against thymocytes and YAC-1 lymphoma targets.

Authors:  T Kamiyama
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.